Immunoscintigraphy with 99mTc labelled F(ab')2 fragments of an anti melanoma monoclonal antibody (225.28S) in patients with metastatic malignant melanoma

Immunoscintigraphy was performed in 25 patients with malignant melanoma using a 99mTc labelled monoclonal antibody (225.28S). In four cases, imaging was repeated following treatment with recombinant gamma interferon. In 11 cases, tissue samples of metastatic lesions were investigated for the express...

Full description

Saved in:
Bibliographic Details
Published in:European Journal Of Nuclear Medicine 1987, Vol.13 (3), p.130-133
Main Authors: Cerny, T, Owens, S E, Mackenzie, S A, Nuttall, P M, Gosh, A K, Smith, D B, Thatcher, N
Format: Article
Language:English
Subjects:
Adult
Aged
Antibodies, Monoclonal
Antibody Specificity
Antigens, Neoplasm
Female
Follow-Up Studies
Humans
Immunoglobulin Fab Fragments
Male
Melanoma - diagnostic imaging
Melanoma-Specific Antigens
Middle Aged
Neoplasm Metastasis
Neoplasm Proteins - immunology
Radionuclide Imaging
Skin Neoplasms - diagnostic imaging
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immunoscintigraphy was performed in 25 patients with malignant melanoma using a 99mTc labelled monoclonal antibody (225.28S). In four cases, imaging was repeated following treatment with recombinant gamma interferon. In 11 cases, tissue samples of metastatic lesions were investigated for the expression of melanoma associated antigens by immunohistochemical techniques. Overall, 59% of known lesions were detected by imaging. The highest rates of detection were in bone, liver and lymph nodes and the lowest in lung, stomach and bowel. Six lesions were detected which had not shown up on routine clinical and radiological examination. There was no evidence of enhanced or induced HMW-MAA expression following interferon treatment. This technique has been found to be useful in staging patients and has been free from side effects.
ISSN:0340-6997
1619-7089
DOI:10.1007/BF00289024